$2.28
0.87% today
Nasdaq, Sep 16, 08:13 pm CET
ISIN
KYG108301006
Symbol
BYSI
Sector
Industry

BeyondSpring Inc. Stock price

$2.30
+0.41 21.69% 1M
-0.71 23.59% 6M
+1.40 155.56% YTD
+1.36 144.68% 1Y
-21.13 90.18% 3Y
-17.81 88.56% 5Y
-14.50 86.31% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.11 5.02%
ISIN
KYG108301006
Symbol
BYSI
Sector
Industry

Key metrics

Market capitalization $92.69m
Enterprise Value $85.93m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 45.71
P/S ratio (TTM) P/S ratio 49.30
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $1.88m
EBIT (operating result TTM) EBIT $-17.05m
EPS (TTM) EPS $-0.40
Short interest 8.82%
Show more

Is BeyondSpring Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

BeyondSpring Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BeyondSpring Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast BeyondSpring Inc.:

Buy
100%

Financial data from BeyondSpring Inc.

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
1.75 1.75
30% 30%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.63 9.63
10% 10%
550%
- Research and Development Expense 15 15
43% 43%
837%
-23 -23
37% 37%
-1,303%
- Depreciation and Amortization 0.30 0.30
74% 74%
17%
EBIT (Operating Income) EBIT -23 -23
38% 38%
-1,321%
Net Profit -21 -21
37% 37%
-1,202%

In millions USD.

Don't miss a Thing! We will send you all news about BeyondSpring Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BeyondSpring Inc. Stock News

Neutral
GlobeNewsWire
about 8 hours ago
Median PFS at 8.63 months and Disease Control Rate of 89.5% in Previously Treated NSCLC Patients after Progression on PD-1/L1 Monotherapy or in Combination with Platinum Doublet Chemotherapy Median PFS at 8.63 months and Disease Control Rate of 89.5% in Previously Treated NSCLC Patients after Progression on PD-1/L1 Monotherapy or in Combination with Platinum Doublet Chemotherapy
Neutral
GlobeNewsWire
about 8 hours ago
Plinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio over Docetaxel Alone: Significant Improvement in Overall Survival, Progression Free Survival, and Objective Response, with additional Significant Reduction of Grade 4 Neutropenia (>80% relative reduction), and Improved Patients' Quality of Life Plinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio ov...
Neutral
GlobeNewsWire
13 days ago
FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announces that it will have an oral presentation on the final efficacy data of Plinabulin and docetaxel combination vs. docetaxel from Dublin-3 phase 3 study in EGFR w...
More BeyondSpring Inc. News

Company Profile

BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

Head office Cayman Islands
CEO Lan Huang
Employees 35
Founded 2010
Website www.beyondspringpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today